Kalaris Therapeutics, Inc. Common Stock KLRS Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $34.43M-65.9% | $98.05M+5,883% | $42.39M+2,116% | $88.43M+1,317% | $100.97M+1,832% | ||
| $62.79M— | $19.93M— | $34.61M+593% | —— | —— | ||
| $98.47M-3.6% | $118.81M+4,459% | $78.18M-36.2% | $91.65M-29.5% | $102.18M-27.8% | ||
| $109.81M+6.5% | $121.74M+1,876% | $81.18M-33.8% | $92.84M-29.1% | $103.09M-28.5% | ||
| $905K-61.9% | $1.28M-17.9% | $494K+869% | $3.68M+3,245% | $2.37M+210% | ||
| $8.08M+13.1% | $9.71M-60.7% | $6.07M+330% | $7.65M+224% | $7.14M-6.7% | ||
| $41.25M+5.2% | $42.92M-24.4% | $39.31M+2,684% | $39.73M+271% | $39.22M+65.5% | ||
| $2K0.0% | $2K— | $2K-81.8% | $2K-81.8% | $2K-81.8% | ||
| -$170.86M-34.8% | -$160M-37.3% | -$150M+78.5% | -$138.11M+80.1% | -$126.76M+81.5% | ||
| $68.56M+7.3% | $78.81M+182% | $41.87M+147% | $53.12M+203% | $63.87M+234% | ||
| $109.81M+6.5% | $121.74M+1,876% | $81.18M-33.8% | $92.84M-29.1% | $103.09M-28.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Kalaris Therapeutics, Inc. Common Stock's total assets?
- Kalaris Therapeutics, Inc. Common Stock (KLRS) holds $109.8M in total assets, up 6.5% year over year.
- How much debt does Kalaris Therapeutics, Inc. Common Stock have?
- Kalaris Therapeutics, Inc. Common Stock carries $1.4M in total debt against $68.6M of shareholders' equity, a debt-to-equity ratio of 0.02.
- How much cash does Kalaris Therapeutics, Inc. Common Stock have?
- Kalaris Therapeutics, Inc. Common Stock holds $34.4M in cash and equivalents.
- Can Kalaris Therapeutics, Inc. Common Stock cover its short-term obligations?
- Its current ratio is 12.19 — current assets exceed current liabilities.
- Where does Kalaris Therapeutics, Inc. Common Stock's balance sheet data come from?
- Every line is extracted from Kalaris Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.